1) To determine if 5 doses of Epo (Erythropoietin) 1000 U/kg (birth weight) intravenous (IV) reduces the rate of death or neurodevelopmental impairment (mild, moderate, or severe) at 24 months of age.
2) To assess safety of Epo.
3) To determine whether Epo decreases the severity of HIE-induced brain injury as evidenced by early MRI and plasma biomarkers of brain injury.
To evaluate how the Medtronic 670G closed loop system impacts clinical and patient-reported outcomes in individuals with type 1 diabetes.
Hydroxychloroquine is given as an investigational drug to relatives of someone with type 1 diabetes who have positive diabetes antibodies in an attempt to prevent or delay the onset of type 1 diabetes. See website for more details https://www.trialnet.org/our-research/prevention-studies/hydroxychloroquine-hcq
To improve patient care and achieve the best health outcomes possible for children with IBD.
We are interested in observing whether and how infants learn when interacting with a robot during a learning assessment contingency paradigm.
The purpose of the study is to collect information from children 0-18 years of age with all types of pancreatitis to determine the number of children diagnosed with this condition, understand the causes and progression of the disease, and review laboratory and imaging findings as well as responses to any treatments given.
Our goal is early identification of deviation from healthy brain development to allow targeted early intervention and improve developmental outcomes.
To determine if a home visitation program for breastfeeding mothers affects the health of their babies.
To better understand the effects of breastfeeding on infant growth and development.
The collection of the research data we hope will help better screening, diagnosing procedures and treatment of brain injury in newborns and identify a connection between MR imaging and neurodevelopmental outcomes.
